– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson’s disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and Director – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN),...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 millionRegulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026 EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGF Cash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitability Management to host conference call today at 8:30 a.m. ETWALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results...

Q4 revenue increased 30% year-over-year to a record $192 million, driven by robust marketplace growth. Q4 marketplace revenue growth accelerated to 33% year-over-year, driven by strong enterprise growth and expanded networks of buyers and suppliers. Q4 gross profit increased 27% year-over-year to a record $75.2 million, driven by strong marketplace growth and marketplace gross margin expansion. Q4 Adjusted EBITDA improved $7.3 million year-over-year to Adjusted EBITDA of $8.4 million, driven by expanding marketplace gross margin and strong operating expense leverage. Strong operating results were driven by consistent execution across growth initiatives: expanding buyer and supplier networks, driving deeper enterprise engagement, further expanding the marketplace platform, growing internationally, and enhancing services offerings.NORTH...

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029 ― CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Expected Cash Runway Now into Mid-2029 Through Execution of Key Clinical, Regulatory and Commercial Milestones Beam to Host Investor Webcast Today, February 24, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq:...

Chassieu, Feb. 24, 2026 (GLOBE NEWSWIRE) —The ANSES evaluation process for the application submitted in March 2025 is currently in its final stage. At the same time, French and Italian agricultural sectors have begun procedures to obtain derogatory marketing authorisations for the use of AXPERA to combat fungal diseases from the start of their production season. At this stage, there is nothing to prevent the marketing authorisation of the product in 2026.Chassieu (France), 23 February 2026 – 6:00 pm – Amoéba (FR0011051598 – ALMIB), industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that the ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has initiated the final phase of its assessment of the...

PRESSRELEASE NANTERRE, FRANCE Tuesday, February 24, 2026    2025 ANNUAL RESULTSPerformance significantly improved in 2025Solid progress on Group key priorities On trajectory to 1.5x leverage at the end of 2026 2025 results demonstrate ongoing margin improvement and deleveraging, backed by strong cash flow generation(All figures presented are before IFRS 5 application, unless stated otherwise)Sales of €26.2bn as reported, or €27bn at constant currency (flat year-on-year) Operating margin at 5.6% of sales, up 40bps vs 2024 Net cash flow of €962m, up 47% vs 2024 Net debt/adjusted EBITDA 1.7x vs 2.0x at end-2024, with net debt down €0.6bn to €6.0bnFull-year net loss of €2.1 billion (after IFRS 5 application), mostly reflecting non-cash exceptional charges related to portfolio transformation and rationalization Planned divestiture...

LERØY SEAFOOD GROUP ASA: SOLID OPERATIONS AND GOOD BIOLOGICAL PERFORMANCE IN THE FOURTH QUARTER  «Operational EBIT in the fourth quarter of 2025 amounted to NOK 758 million. The result reflects good underlying operations across the Group, with solid contributions from Farming and a very strong quarter in the Value-Added Processing, Sales and Distribution (VAP S&D) segment. Although the year has been characterised by low salmon prices, the fourth quarter demonstrates the effect of a robust and fully integrated value chain», says Henning Beltestad, CEO of Lerøy Seafood Group. FARMING: IMPROVING PRICES TOWARDS THE END OF THE QUARTER AND GOOD BIOLOGICAL PERFORMANCE Operational EBIT in the farming segment amounted to NOK 564 million in the fourth quarter of 2025, somewhat lower than in the corresponding period last year. «Prices for salmon...

GUADALAJARA, Mexico, Feb. 23, 2026 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) reports its consolidated results for the fourth quarter ended December 31, 2025 (4Q25). Figures are unaudited and prepared following International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). Summary of Results 4Q25 vs. 4Q24The sum of aeronautical and non-aeronautical services revenues increased by Ps. 911.4 million, or 12.8%. Total revenues increased by Ps. 267.1 million, or 2.8%. Cost of services increased by Ps. 426.8 million, or 28.1%. Income from operations increased by Ps. 322.1 million, or 8.4%. EBITDA increased by Ps. 357.3 million, or 7.5%, an increase from Ps. 4,757.0 million in 4Q24 to Ps. 5,114.3 million in...

Record 4Q and Full Year Performance at Work Truck Solutions; Record Parts & Accessories Sales at Work Truck Attachments Full Year 2025 Highlights*Consolidated Net Sales increased 15.4% to $656.1 million Winter weather drove robust Parts & Accessories sales across the company, particularly in 4Q Delivered Diluted Earnings per Share (EPS) of $1.96; Adjusted Diluted EPS increased 52.0% to $2.24 Both segments produced Net Sales and Adjusted EBITDA growth for both 4Q and Full Year 2025   Acquired Venco Venturo in 4Q, a well-established provider of truck-mounted service cranes and dump hoists Outlined 2026 full year outlook with Adjusted EPS range of $2.25 – $2.85*Compared to full year 2024 financials. MILWAUKEE, Feb. 23, 2026 (GLOBE NEWSWIRE) — Douglas Dynamics, Inc. (NYSE: PLOW), North America’s premier manufacturer...